Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Synthesis and biological evaluation of RGD and isoDGR peptidomimetic-α-amanitin conjugates for tumor-targeting.

Bodero L, López Rivas P, Korsak B, Hechler T, Pahl A, Müller C, Arosio D, Pignataro L, Gennari C, Piarulli U.

Beilstein J Org Chem. 2018 Feb 14;14:407-415. doi: 10.3762/bjoc.14.29. eCollection 2018.

2.

Exploring Natural Product Fragments for Drug and Probe Discovery.

Pahl A, Waldmann H, Kumar K.

Chimia (Aarau). 2017 Oct 25;71(10):653-660. doi: 10.2533/chimia.2017.653.

PMID:
29070410
3.

A biosynthesis-inspired approach to over twenty diverse natural product-like scaffolds.

Firth JD, Craven PG, Lilburn M, Pahl A, Marsden SP, Nelson A.

Chem Commun (Camb). 2016 Jul 28;52(63):9837-40. doi: 10.1039/c6cc04662b.

4.

Reversible Inhibitors Arrest ClpP in a Defined Conformational State that Can Be Revoked by ClpX Association.

Pahl A, Lakemeyer M, Vielberg MT, Hackl MW, Vomacka J, Korotkov VS, Stein ML, Fetzer C, Lorenz-Baath K, Richter K, Waldmann H, Groll M, Sieber SA.

Angew Chem Int Ed Engl. 2015 Dec 21;54(52):15892-6. doi: 10.1002/anie.201507266. Epub 2015 Nov 13.

PMID:
26566002
5.

Phenyl Esters Are Potent Inhibitors of Caseinolytic Protease P and Reveal a Stereogenic Switch for Deoligomerization.

Hackl MW, Lakemeyer M, Dahmen M, Glaser M, Pahl A, Lorenz-Baath K, Menzel T, Sievers S, Böttcher T, Antes I, Waldmann H, Sieber SA.

J Am Chem Soc. 2015 Jul 8;137(26):8475-83. doi: 10.1021/jacs.5b03084. Epub 2015 Jun 29.

PMID:
26083639
6.

TP53 loss creates therapeutic vulnerability in colorectal cancer.

Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X.

Nature. 2015 Apr 30;520(7549):697-701. doi: 10.1038/nature14418. Epub 2015 Apr 22.

7.

Label-free in situ monitoring of histone deacetylase drug target engagement by matrix-assisted laser desorption ionization-mass spectrometry biotyping and imaging.

Munteanu B, Meyer B, von Reitzenstein C, Burgermeister E, Bog S, Pahl A, Ebert MP, Hopf C.

Anal Chem. 2014 May 20;86(10):4642-7. doi: 10.1021/ac500038j. Epub 2014 Mar 11.

PMID:
24559101
8.

No evidence for local adaptation in an invasive alien plant: field and greenhouse experiments tracing a colonization sequence.

Pahl AT, Kollmann J, Mayer A, Haider S.

Ann Bot. 2013 Dec;112(9):1921-30. doi: 10.1093/aob/mct246. Epub 2013 Nov 7.

9.

Conceptual frameworks and methods for advancing invasion ecology.

Heger T, Pahl AT, Botta-Dukát Z, Gherardi F, Hoppe C, Hoste I, Jax K, Lindström L, Boets P, Haider S, Kollmann J, Wittmann MJ, Jeschke JM.

Ambio. 2013 Sep;42(5):527-40. doi: 10.1007/s13280-012-0379-x. Epub 2013 Mar 27.

10.

Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.

Sann H, Erichsen Jv, Hessmann M, Pahl A, Hoffmeyer A.

Life Sci. 2013 Apr 9;92(12):708-18. doi: 10.1016/j.lfs.2013.01.028. Epub 2013 Feb 8.

PMID:
23399699
11.

Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors.

Tauber S, Paulsen K, Wolf S, Synwoldt P, Pahl A, Schneider-Stock R, Ullrich O.

PLoS One. 2012;7(11):e48272. doi: 10.1371/journal.pone.0048272. Epub 2012 Nov 6.

12.

miR-9 enhances IL-2 production in activated human CD4(+) T cells by repressing Blimp-1.

Thiele S, Wittmann J, Jäck HM, Pahl A.

Eur J Immunol. 2012 Aug;42(8):2100-8. doi: 10.1002/eji.201142203.

13.

CT fluoroscopy-guided percutaneous vertebroplasty in spinal malignancy: technical results, PMMA leakages, and complications in 202 patients.

Trumm CG, Pahl A, Helmberger TK, Jakobs TF, Zech CJ, Stahl R, Paprottka PM, Sandner TA, Reiser MF, Hoffmann RT.

Skeletal Radiol. 2012 Nov;41(11):1391-400.

PMID:
22286549
14.

CT fluoroscopy-guided percutaneous vertebroplasty in patients with multiple myeloma: analysis of technical results from 44 sessions with 67 vertebrae treated.

Trumm C, Jakobs T, Pahl A, Stahl R, Helmberger T, Paprottka P, Reiser M, Hoffmann RT.

Diagn Interv Radiol. 2012 Jan-Feb;18(1):111-20. doi: 10.4261/1305-3825.DIR.4226-11.1. Epub 2011 Oct 17.

15.

Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury.

Schuh K, Pahl A.

Biochem Pharmacol. 2009 Jun 15;77(12):1827-34. doi: 10.1016/j.bcp.2009.03.012. Epub 2009 Mar 24.

PMID:
19428337
16.

Drug dosing error with drops: severe clinical course of codeine intoxication in twins.

Hermanns-Clausen M, Weinmann W, Auwärter V, Ferreirós N, Trittler R, Müller C, Pahl A, Superti-Furga A, Hentschel R.

Eur J Pediatr. 2009 Jul;168(7):819-24. doi: 10.1007/s00431-008-0842-7. Epub 2008 Oct 21.

PMID:
18936971
17.

Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3.

Veldman C, Pahl A, Hertl M.

Immunology. 2009 May;127(1):40-9. doi: 10.1111/j.1365-2567.2008.02932.x. Retraction in: Immunology. 2011 Sep;134(1):107.

18.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

19.

Preclinical modelling using nasal epithelial cells for the evaluation of herbal extracts for the treatment of upper airway diseases.

Pahl A.

Planta Med. 2008 May;74(6):693-6. doi: 10.1055/s-2007-993764. Epub 2008 Jan 10. Review.

PMID:
18186014
20.

Prospective use of CYP pharmacogenetics and medication analysis to facilitate improved therapy - a pilot study.

Chialda L, Griffith LS, Heinig A, Pahl A.

Per Med. 2008 Jan;5(1):37-45. doi: 10.2217/17410541.5.1.37.

PMID:
29783392
21.

The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients.

Dragonas C, Wagner JT, Heppner HJ, Bertsch T, Muhlberg W, Wicklein S, Pahl A, Diewald C, Bachmakov I, Sieber CC, Fromm MF.

Eur J Clin Pharmacol. 2008 Apr;64(4):367-72. Epub 2007 Dec 16.

PMID:
18080812
22.
23.

Controlled adjustment of PCR amplification.

Pahl A.

Anal Biochem. 2007 Oct 15;369(2):262-4. Epub 2007 Jun 3. No abstract available.

PMID:
17603994
24.

MDR1 genotype-dependent regulation of the aldosterone system in humans.

Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE.

Pharmacogenet Genomics. 2007 Feb;17(2):137-44.

PMID:
17301693
25.

Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF.

Puljic R, Benediktus E, Plater-Zyberk C, Baeuerle PA, Szelenyi S, Brune K, Pahl A.

Eur J Pharmacol. 2007 Feb 28;557(2-3):230-5. Epub 2006 Nov 14.

PMID:
17174948
26.

Pharmacogenomics of asthma.

Pahl A, Benediktus E, Chialda L.

Curr Pharm Des. 2006;12(25):3195-206. Review.

PMID:
17020528
27.

Synergistic effects of the anti-cholinergic R,R-glycopyrrolate with anti-inflammatory drugs.

Pahl A, Bauhofer A, Petzold U, Cnota PJ, Maus J, Brune K, Szelenyi S.

Biochem Pharmacol. 2006 Dec 15;72(12):1690-6. Epub 2006 Sep 25.

PMID:
16996482
28.

Biomimetics: its practice and theory.

Vincent JF, Bogatyreva OA, Bogatyrev NR, Bowyer A, Pahl AK.

J R Soc Interface. 2006 Aug 22;3(9):471-82. Review.

29.

Are there any realistic chances to develop new drugs for asthma?

Amon A, Pahl A, Szelenyi I.

Drug News Perspect. 2006 May;19(4):189-200. Review.

PMID:
16823494
31.

Is asthma research in dead end?

Amon A, Pahl A, Szelenyi I.

Exp Toxicol Pathol. 2006 Jun;57 Suppl 2:45-7. Epub 2006 Apr 11. Review.

PMID:
16581236
32.

Can corticosteroids be beaten in future asthma therapy?

Amon A, Pahl A, Szelenyi I.

Pharmazie. 2006 Feb;61(2):122-4. Review.

PMID:
16526559
33.

Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells.

Veldman C, Pahl A, Beissert S, Hansen W, Buer J, Dieckmann D, Schuler G, Hertl M.

J Immunol. 2006 Mar 1;176(5):3215-22. Erratum in: J Immunol. 2012 Oct 1;189(7):3779.

34.

CYP3A5 genotype is associated with elevated blood pressure.

Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE.

Pharmacogenet Genomics. 2005 Oct;15(10):737-41.

PMID:
16141800
36.

Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.

Egger T, Dormann H, Ahne G, Pahl A, Runge U, Azaz-Livshits T, Neubert A, Criegee-Rieck M, Gassmann KG, Brune K.

Drugs Aging. 2005;22(3):265-72.

PMID:
15813658
37.
38.

Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype.

Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, Pahl A, Brune K, Narumiya S, Müller U, Zeilhofer HU.

J Clin Invest. 2005 Mar;115(3):673-9.

39.

Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate.

Szelenyi I, Hermann R, Petzold U, Pahl A, Hochhaus G.

Pharmazie. 2004 May;59(5):409-11.

PMID:
15212311
40.

Protection against progressive leishmaniasis by IFN-beta.

Mattner J, Wandersee-Steinhäuser A, Pahl A, Röllinghoff M, Majeau GR, Hochman PS, Bogdan C.

J Immunol. 2004 Jun 15;172(12):7574-82.

41.

RNA-based drug screening using automated RNA purification and real-time RT-PCR1.

Ullmann S, Hage T, Draheim R, Egerland U, Oelmüller U, Brune K, Pahl A.

J Biomol Screen. 2004 Mar;9(2):95-102.

PMID:
15006132
43.
44.

Stabilization of gene expression profiles in blood after phlebotomy.

Pahl A, Brune K.

Clin Chem. 2002 Dec;48(12):2251-3. No abstract available.

45.

Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles.

Schmitt C, Humeny A, Becker CM, Brune K, Pahl A.

Clin Chem. 2002 Oct;48(10):1661-7.

46.

Gene expression changes in blood after phlebotomy: implications for gene expression profiling.

Pahl A, Brune K.

Blood. 2002 Aug 1;100(3):1094-5. No abstract available.

47.

Asthma therapy in the new millennium.

Pahl A, Szelenyi I.

Inflamm Res. 2002 Jun;51(6):273-82. Review.

PMID:
12088267
48.

NMR solution structure and dynamics of the peptidyl-prolyl cis-trans isomerase domain of the trigger factor from Mycoplasma genitalium compared to FK506-binding protein.

Vogtherr M, Jacobs DM, Parac TN, Maurer M, Pahl A, Saxena K, Rüterjans H, Griesinger C, Fiebig KM.

J Mol Biol. 2002 May 10;318(4):1097-115.

PMID:
12054805
49.

Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787.

Pahl A, Zhang M, Török K, Kuss H, Friedrich U, Magyar Z, Szekely J, Horvath K, Brune K, Szelenyi I.

J Pharmacol Exp Ther. 2002 May;301(2):738-46.

50.

Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy.

Pahl A, Zhang M, Kuss H, Szelenyi I, Brune K.

Br J Pharmacol. 2002 Apr;135(8):1915-26.

Supplemental Content

Support Center